A randomized, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the efficacy and safety of HY209 gel in patients with mild to moderate atopic Dermatitis(AD)
NCT ID NCT06024499
Summary
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cahaba Dermatology Skin Health Center
Birmingham, Alabama, 35244, United States
-
Continental Clinical Solutions, LLC
Towson, Maryland, 21204, United States
-
Gachon University Gil Medical Center
Seoul, South Korea
-
L.A. Universal Research Center, Inc.
Los Angeles, California, 90057, United States
-
RAOOF MD Dermatology
Encino, California, 16133, United States
-
Revival Research Institute, LLC
Southfield, Michigan, 19505, United States
-
Sadick Dermatology
New York, New York, 10075, United States
-
Seoul National University Bundang Hospital
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
Zenith Research Inc.
Los Angeles, California, 90212, United States
Conditions
Explore the condition pages connected to this study.